The success rate of trials from pre-clinical through phase 1 is only 35%. In oncology the overall success rate through approval is only 3.4%.
What gives us a leg up is the groundwork already laid down in trials by Maraviroc. We know CCR5 blocking translates from mice models to humans.
(0)
(0)
CytoDyn Inc (CYDY) Stock Research Links
-
-
-
-
-
-
-